Alexander Oboro
Family · Mill Hall, PANPI 1346807849
Payments from drug & device makers
Across 287 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$610
- Teva Pharmaceuticals USA, Inc.$464
- Otsuka America Pharmaceutical, Inc.$463
- Alkermes, Inc.$438
- plus $587 from 7 others
What the payments were for
- Food & beverage$4,833100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $1,165 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $1,118 |
| Neurocrine Biosciences, Inc. | 29 | $610 |
| Teva Pharmaceuticals USA, Inc. | 27 | $464 |
| Otsuka America Pharmaceutical, Inc. | 28 | $463 |
| Alkermes, Inc. | 25 | $438 |
| Johnson & Johnson | 12 | $219 |
| Axsome Therapeutics, Inc. | 6 | $134 |
| Lundbeck LLC | 7 | $104 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Corium, LLC | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Indivior Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$125
How this compares
$4,846 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 36 | $285,747 |
| AustedoDeutetrabenazine | 12 | $83,599 |
| VraylarCariprazine Hcl | 35 | $47,786 |
| Risperdal ConstaRisperidone Microspheres | 15 | $31,385 |
| Invega SustennaPaliperidone Palmitate | 12 | $28,465 |
| RexultiBrexpiprazole | 12 | $16,968 |
| Olanzapine | 211 | $7,931 |
| Vilazodone Hcl | 33 | $4,652 |
| Divalproex Sodium ErDivalproex Sodium | 52 | $4,302 |
| Aripiprazole | 52 | $4,073 |
| Quetiapine Fumarate | 239 | $3,276 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 151 | $2,406 |
| Trazodone Hcl | 167 | $2,152 |
| Sertraline Hcl | 199 | $2,058 |
| Buspirone Hcl | 145 | $2,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $610 | $285,74736 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $464 | $83,59912 claims |
| Johnson & JohnsonRisperdal Consta, Invega Sustenna | $219 | $59,85027 claims |
| AbbVieVraylar | $1,165 | $47,78635 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $463 | $16,96812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.
Other family in Mill Hall
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.